 MONT-SAINT-GUIBERT, Belgium, Jan. 13, 2020 GLOBE NEWSWIRE -- Celyad Euronext Brussels and Paris, and Nasdaq: CYAD, a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, today announced the successful administration of the next-generation, NKG2D-based candidate CYAD-02 to a relapsedrefractory acute myeloid leukemia rr AML patient enrolled in the Phase 1 CYCLE-1 trial. 